Clinical trials: Cushing Syndrome
Cushing Syndrome
Appropriate Limit Value for 1 mg DST in Patients With Chronic Renal Failure
In this study, we aimed to determine a specific cut-off value for 1mg DST to prevent false positivity usually seen in CRF patients according to the standard cut-off value of 1.8 mcg/dl.
- Trial name
- NCT05568602
- Testing
- Dexamethasone suppression test
- Where
- Turkey (Türkiye)
- Volunteers
- 1,034 people
- Sponsor
- Marmara University
Endogenous Cushing's Syndrome
Treatment for Endogenous Cushing's Syndrome
The primary objectives of this study are to evaluate the clinical responder rate, defined as the proportion of subjects with normal UFC after 6 months of treatment with COR-003 in the Maintenance Phase without dose increase, and…
- Trial name
- SONICS (NCT01838551)
- Testing
- Levoketoconazole
- Where
- 42 sites in United States, Belgium and 13 more
- Volunteers
- 94 people
- Sponsor
- Cortendo AB
Cushing Syndrome
Quality of Life, Fatigue and Cognitive, Affective and Emotional Dysfunction in Patients With Cushing's Syndrome
This is a prospective, multi-center, case-control study where neurocognitive function will be evaluated in 36 patients with Cushing syndrome (CS) and 36 controls matched for age, gender and education.
- Trial name
- NCT03211624
- Where
- 3 sites in Netherlands, Spain and 1 more
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Göteborg University
Cushing Syndrome
The Circadian Rhythm in CusHing SyndrOme in Active Phase and dUring RemiSsion (TheHOURS)
This is an observational, open, prospective multi-centre study designed to evaluate melatonin and cortisol circadian rhythm, immunological profile and anthropometric parameters in Cushing Syndrome patients during active Remission…
- Trial name
- TheHOURS (NCT03343470)
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- University of Roma La Sapienza
Cushing's Syndrome
Diagnostic Performance of Screening Tests for Cushing s Syndrome
This study will test the accuracy of screening tests for Cushing s syndrome in overweight people with signs of the disorder. Cushing s syndrome is a rare disorder caused by excess production of the hormone cortisol.
- Trial name
- NCT00361777
- Where
- 2 sites in United States
- Volunteers
- 471 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Cushing Syndrome
Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CT
The incidence of Cushing syndrome (CS) is 1.2-3.2 cases per million per year, of which adrenocorticotropic Hormone (ACTH)-dependent disease comprises approximately 70-80% of cases.
- Trial name
- Ga-68 mDesmo (NCT06962202)
- Where
- India
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Cushing's Syndrome
Hippocampal Complex Volume and Memory Dysfunction in Cushing's Syndrome
OBJECTIVES: I. Evaluate whether chronic hypercortisolemia is specifically toxic to hippocampal cells and causes structural reduction of hippocampal volume in patients with Cushing's syndrome. II.
- Trial name
- NCT00004326
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Center for Research Resources (NCRR)
Cushing's Disease
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease.
- Trial name
- NCT01374906
- Testing
- pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg
- Where
- 82 sites in United States, Argentina and 18 more
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Syndrome, Pituitary Adenoma
Defining the Genetic Basis for the Development of Primary Pigmented Nodular Adrenocortical Disease (PPNAD) and the Carney Complex
Lentiginosis refers to groups of diseases marked by the presence of pigmented spots on the skin. These conditions are most commonly associated with multiple tumors and changes in hormone producing glands.
- Conditions
- Cushing's Syndrome, Pituitary Adenoma, Carney Complex, Primary Pigmented Nodular Adrenocortical Disease
- Trial name
- NCT00001452
- Testing
- oCRH
- Where
- United States
- Volunteers
- 1,387 people
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Hypercortisolism, Diabetes Mellitus, Type 2
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
This is a Phase 4 study with 2 parts: Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes (T2D) (hemoglobin A1c ≥7.5%)…
- Trial name
- NCT05772169
- Testing
- Mifepristone 300 MG [Korlym]
- Where
- 36 sites in United States
- Volunteers
- 1,113 people
- Sponsor
- Corcept Therapeutics
Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism Due to Nodular Hyperplasia
First-in-human Evaluation of [18F]CETO
Purpose of this clinical phase 1 trial was to determine if para-chloro-2-[18F]fluoroethyletomidate positron emission computed tomography ([18F]CETO-positron emission computed tomography(PET)/computed tomography(CT)) can be used…
- Conditions
- Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism Due to Nodular Hyperplasia, Adrenal Cushing Syndrome, Non-Secretory Adrenal Adenoma
- Trial name
- NCT05361083
- Testing
- F18CETO
- Where
- Sweden
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Uppsala University
Hypercortisolism
A Study of the Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas
This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, and safety of relacorilant to treat hypercortisolism in patients with cortisol-secreting adrenal adenoma or hyperplasia associated with…
- Trial name
- GRADIENT (NCT04308590)
- Testing
- Relacorilant
- Where
- 45 sites in United States, Austria and 7 more
- Volunteers
- 137 people
- Sponsor
- Corcept Therapeutics
Cushing Syndrome
Alterations of Muscle Secretome Associated With Muscle Atrophy Caused by Glucocorticoids
Several studies have shown that lean mass, in particular muscle mass, is an excellent predictive survival factor in many diseases.
- Trial name
- MYOSECRET (NCT03229395)
- Where
- Belgium
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Mineralocorticoid Excess, Primary Aldosteronism
Dynamic Hormone Profiling and Multimodal Data Capture in Primary Aldosteronism
This study is a observational study applying 24-hour microdialysis methodology to perform dynamic multisteroid adrenal hormone profiling of patients with suspected or confirmed PA.
- Conditions
- Mineralocorticoid Excess, Primary Aldosteronism, Hypercortisolism
- Trial name
- NCT06495983
- Testing
- dynamic microdialysis sampling
- Where
- Norway
- Volunteers
- 80 people
- Sponsor
- Haukeland University Hospital
Endocrine System Disease, Cardiovascular Imaging
Cardiac Steatosis in Cushing's Syndrome
This study aims at evaluating the myocardial triglyceride content and cardiac structure and function, using 1H magnetic resonance spectroscopy and cardiac magnetic resonance imaging, in patients with Cushing's syndrome before and…
- Trial name
- CORTICOEUR (NCT02202902)
- Testing
- 1H magnetic resonance spectroscopy and CMRI
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Obesity, Morbid
Study of the Steroid Hormone Milieu in Obese Patients
The aim of this observational study is to evaluate the actual secretion of cortisol and testosterone in obese male subjects, together with the receptor sensitivity to these hormones in order to understand whether the hormonal…
- Trial name
- MiSterO (NCT06341699)
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- Istituto Auxologico Italiano
Adult Glucocorticoid Excess, Adult Adrenal Insufficiency
Genomic and Metabolomic Markers Reflecting the Complications of Hypercortisolism (CUSHINGOMICS)
The excess of glucocorticoid, whether endogenous or exogenous, results in Cushing's syndrome, associating a particular distribution of fats (accumulation in the face and trunk), a decrease in the thickness of the muscles…
- Trial name
- CUSHINGOMICS (NCT04840693)
- Testing
- Biological samples, Complications
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Adrenocortical Carcinoma
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
This study will investigate the safety and efficacy of Relacorilant in combination with Pembrolizumab for Patients with Adrenocortical Carcinoma which Produces Too Much Stress Hormone (Cortisol).
- Trial name
- NCT04373265
- Testing
- Relacorilant, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Corcept Therapeutics
Endocrine Disorders, Adiposity
Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models
The goal of this observational study is to evaluate, retrospectively and prospectively, the effect of different hormonal and neuropeptide dysfunctions on the body composition of patients suffering from hypothalamic-pituitary…
- Conditions
- Endocrine Disorders, Adiposity, Pituitary Adenoma, Cushing Syndrome
- Trial name
- NCT06326853
- Volunteers
- 200 people
- Sponsor
- IRCCS San Raffaele
Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS)
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and…
- Trial name
- NCT07104812
- Testing
- Osilodrostat 1 MG
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic